公开(公告)号：US20240238241A1

公开(公告)日：2024-07-18

申请号：US18292496

申请日：2022-07-28

申请人： JAPAN SCIENCE AND TECHNOLOGY AGENCY

发明人： Kiyoko FUKAMI ,  Reiko SATOW

IPC分类号： A61K31/365 ,  A61K31/133 ,  A61K31/366 ,  A61K31/407 ,  A61K31/585 ,  A61P35/00 ,  C12N15/113

CPC分类号： A61K31/365 ,  A61K31/133 ,  A61K31/366 ,  A61K31/407 ,  A61K31/585 ,  A61P35/00 ,  C12N15/113

摘要： The present invention provides a pharmaceutical composition that suppresses cell proliferation and has an anti-cancer effect with respect to pancreatic cancer and bile duct cancer. The present invention relates to a pharmaceutical composition containing, as an active ingredient, a substance that reduces an intracellular content of a ZIC5 protein, where the composition is used for treatment of pancreatic cancer or bile duct cancer; the pharmaceutical composition further containing an anti-cancer agent other than the substance that reduces the intracellular content of the ZIC5 protein; and the pharmaceutical composition further containing an anti-cancer agent other than the substance that reduces the intracellular content of the ZIC5 protein.

公开(公告)号：US11986459B2

公开(公告)日：2024-05-21

申请号：US17713576

申请日：2022-04-05

申请人： University of South Florida

发明人： Bill J. Baker ,  Kyle Rohde ,  Bingjie Yang ,  Marisa Fuse

IPC分类号： A61K31/12 ,  A61K31/133 ,  A61K31/145 ,  A61K31/192 ,  A61K31/235 ,  A61K31/343 ,  A61K31/352 ,  A61K31/365 ,  A61K31/366 ,  A61K31/4015 ,  A61K31/4045 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/454 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/505 ,  A61K31/7036 ,  A61P31/06

CPC分类号： A61K31/366 ,  A61K31/12 ,  A61K31/133 ,  A61K31/145 ,  A61K31/192 ,  A61K31/235 ,  A61K31/343 ,  A61K31/352 ,  A61K31/365 ,  A61K31/4015 ,  A61K31/4045 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/454 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/505 ,  A61K31/7036 ,  A61P31/06

摘要： The present disclosure provides methods for the treatment of infections with Mycobacterium such as tuberculosis or leprosy.

公开(公告)号：US11974972B1

公开(公告)日：2024-05-07

申请号：US18388696

申请日：2023-11-10

申请人： Joong Ho Moon ,  Michelle Miranda

发明人： Joong Ho Moon ,  Michelle Miranda

IPC分类号： A61K8/43 ,  A61K31/133 ,  A61K31/155 ,  A61K31/17 ,  A61K31/277 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/498 ,  A61K31/5377 ,  A61P31/04 ,  A61P31/06 ,  C07C279/12 ,  C07D295/215 ,  C08G65/00 ,  C08G71/02

CPC分类号： A61K31/17 ,  A61K31/133 ,  A61K31/277 ,  A61K31/4409 ,  A61K31/47 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/498 ,  A61K31/5377 ,  A61P31/06 ,  C07C279/12 ,  C07D295/215 ,  C08G65/00 ,  C08G71/02 ,  C07C2601/16

摘要： The subject invention provides oligo(carbamoylated guanidine)s (OCGs) having fast and selective mycobactericidal effects via disruption of the mycobacterial membrane potential. OCGs also potentiates bedaquiline, an oxidative phosphorylation-targeting anti-TB drug. The combination of OCG and anti-TB drug can be used as an effective therapy for treating tuberculosis.

公开(公告)号：US11974969B2

公开(公告)日：2024-05-07

申请号：US17042931

申请日：2019-03-29

申请人： INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES

发明人： Chengyu Jiang ,  Yuhao Qin ,  Xiaoyun Li ,  Cong Zhang

IPC分类号： A61K31/133 ,  A61K9/00 ,  A61K31/14 ,  A61K31/661 ,  A61K31/7016 ,  A61K31/702 ,  A61K47/18 ,  A61K47/24 ,  A61P35/00 ,  C07C69/003 ,  C07C69/587 ,  C07C215/10 ,  C07C233/18 ,  C07F9/10 ,  C12N15/113

CPC分类号： A61K31/133 ,  A61K9/0053 ,  A61K31/14 ,  A61K31/661 ,  A61K31/7016 ,  A61K31/702 ,  A61K47/18 ,  A61K47/24 ,  A61P35/00 ,  C07C69/003 ,  C07C69/587 ,  C07C215/10 ,  C07C233/18 ,  C07F9/10 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/32

摘要： The invention provides an artificially synthesized single sphingosine lipid and use of delivering a nucleic acid thereof. More particularly, the invention provides Use or method for delivering a nucleic acid to a cell or a subject using a compound of Formula (I), a stereoisomer or a pharmaceutical acceptable salt thereof, or a combination comprising a compound of Formula (I), a stereoisomer or a pharmaceutical acceptable salt thereof,

公开(公告)号：US20240051914A1

公开(公告)日：2024-02-15

申请号：US17998119

申请日：2022-03-18

申请人： Wuxi No.2 People's Hospital

发明人： Zejun Pei ,  Xin Sun ,  Jingyu Zhu ,  Xin Wang ,  Xin Yang ,  Renjing Hu ,  Yi Qian

IPC分类号： C07C215/10 ,  A61K31/133 ,  C07C213/10 ,  C07C213/08 ,  A61P35/00 ,  A61P31/10

CPC分类号： C07C215/10 ,  A61K31/133 ,  C07C213/10 ,  C07C213/08 ,  A61P35/00 ,  A61P31/10

摘要： The invention belongs to the field of organic synthesis, and specifically relates to the hexadecane tromethamine compound which has the following structure:




and provides the synthesis method of the hexadecane tromethamine compound, and the application of the hexadecane tromethamine compound in anti-tumor and antifungal aspects. The invention fills the gaps in the synthesis process of the hexadecane tromethamine compound and the application of the hexadecane tromethamine compound in anti-tumor and antifungal aspects.

公开(公告)号：US20230330041A1

公开(公告)日：2023-10-19

申请号：US18043068

申请日：2021-08-20

申请人： BEIJING CHANGSHENG PHARMACEUTICAL TECHNOLOGY CO., LTD.

发明人： Guowen LI ,  Xianhua CHEN

IPC分类号： A61K31/133 ,  A61P19/06

CPC分类号： A61K31/133 ,  A61P19/06

摘要： A use of a tris (hydroxymethyl) aminomethane pharmaceutically acceptable salt or a composition formed by tris (hydroxymethyl) aminomethane and an inorganic acid or an organic acid in the preparation of drugs for treating or preventing hyperuricemia, gout, acute and chronic arthritis, gouty nephropathy, uric acid nephrolithiasis and related diseases. A use of tris (hydroxymethyl) aminomethane in the preparation of topical pharmaceutical compositions for preventing or treating gout and gouty arthritis by topical and transdermal administration.

公开(公告)号：US20230263814A1

公开(公告)日：2023-08-24

申请号：US18024040

申请日：2021-08-30

申请人： Insmed Incorporated

发明人： Kevin MANGE ,  Dayton YUEN ,  Zhanna JUMADILOVA

IPC分类号： A61K31/7036 ,  A61K9/127 ,  A61K9/00 ,  A61K31/133 ,  A61K31/7052 ,  A61K31/7048 ,  A61P31/04

CPC分类号： A61K31/7036 ,  A61K9/127 ,  A61K9/0078 ,  A61K31/133 ,  A61K31/7052 ,  A61K31/7048 ,  A61P31/04

摘要： Provided is a method for treating a newly diagnosed and untreated MAC lung infection comprising administering to the lungs of a patient for an administration period of at least about 6 months, a pharmaceutical composition comprising amikacin, or a pharmaceutically acceptable salt thereof, The pharmaceutical composition is aerosolized via a nebulizer to provide an aerosolized pharmaceutical composition comprising a mixture of free amikacin, or a pharmaceutically acceptable salt thereof, and liposomal complexed amikacin, or a pharmaceutically acceptable salt thereof, and the aerosolized pharmaceutical composition is administered via the nebulizer to the lungs of the patient once daily in a single dosing session. The treating comprises improving a respiratory symptom score as defined by one or more patient reported outcomes, during or subsequent to the administration period.

公开(公告)号：US11717578B2

公开(公告)日：2023-08-08

申请号：US16637082

申请日：2018-08-09

申请人： University of Cincinnati

发明人： Clifford E. Larrabee ,  Mary R. Warmin

IPC分类号： A61K47/69 ,  A61P35/00 ,  A61K9/00 ,  A61K31/133 ,  A61K31/195 ,  A61K31/4453 ,  A61K31/4965 ,  A61K31/704 ,  A61K31/7068 ,  B82Y5/00

CPC分类号： A61K47/6907 ,  A61K9/0019 ,  A61K31/133 ,  A61K31/195 ,  A61K31/4453 ,  A61K31/4965 ,  A61K31/704 ,  A61K31/7068 ,  A61P35/00 ,  B82Y5/00

摘要： Targeted drug delivery systems comprising a therapeutic agent solubilized with undecylenic acid (UA)-based nanocarrier vesicles that may be polymerized or provided as an mPEG ester are provided to achieve targeted delivery of, for example, ROS-activated cytotoxic agents to cancer cells exhibiting high levels of ROS. Methods utilizing photodynamic and sonodynamic generation of ROS to enhance targeted delivery are also provided.

公开(公告)号：US20230240984A1

公开(公告)日：2023-08-03

申请号：US17976737

申请日：2022-10-28

申请人： Abela Pharmaceuticals, Inc.

发明人： Colette Cozean ,  Jesse Cozean ,  Rodney Benjamin ,  Anthony Keller

IPC分类号： A61K9/00 ,  A61K31/10 ,  A61K45/06 ,  A61K31/133 ,  A61K31/17 ,  A61K31/4409 ,  A61K31/496 ,  A61K31/4965 ,  A61K31/7036

CPC分类号： A61K9/0053 ,  A61K9/0014 ,  A61K31/10 ,  A61K31/17 ,  A61K31/133 ,  A61K31/496 ,  A61K31/4409 ,  A61K31/4965 ,  A61K31/7036 ,  A61K45/06 ,  Y02A50/30

摘要： Embodiments of the invention relate generally to the use of formulations comprising DMSO and MSM to treat arthritis (such as osteoarthritis), pain, inflammation, and/or degeneration. DMSO and MSM formulations are administered orally and/or topically in several embodiments and provide effective treatment of both chronic and acute symptoms of arthritis (e.g., osteoarthritis), pain, inflammation, and/or degeneration. Solid forms of DMSO are provided in several embodiments.

公开(公告)号：US20230144385A1

公开(公告)日：2023-05-11

申请号：US17995341

申请日：2021-03-05

申请人： METANOI THERAPEUTICS, INC.

发明人： Guilherme H.C. CANTUARIA

IPC分类号： A61K31/133 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K31/133 ,  A61P35/00 ,  C07K16/2818

摘要： Monoethanolamine (Etn) displays strong in vitro and in vivo efficacy in prostate cancer cell lines and xenograft models, respectively, as well as in cell lines from diverse cancer types. Etn is a pro-drug, which upon entry into tumor cells, is converted into cytotoxic phosphoethanolamine (PhosE). Etn treatment potently down-regulates HIF-1α and drives a catastrophic uncoupling of multiple pathways to induce metabolic crisis and cell death, selectively in tumor cells, while sparing normal cells. Importantly, the ovarian cancer cell line OVCAR3 was more sensitive to Etn than all the prostate, breast, colon, and pancreatic cancer cell lines tested. An Etn-based formulation with favorable pharmacokinetics/pharmacodynamics (PK/PD) can therefore in some embodiments be used as single therapeutic for EOC or OCCC.